Q4 2022 Results

Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 financial results in line with guidance; ahead on Core Oplnc Group full year guidance (Q3 earnings October 2022) In cc FY 2022 vs. PY Innovative Medicines Sales to grow mid single digit +4% Core Opinc to grow mid to high single digit, ahead of sales +8% Sandoz Sales to grow low to mid single digit Core Oplnc to grow low single digit +4% -1% Group Sales to grow mid single digit Core Oplnc to grow mid single digit +4% +8% 35 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation